Background {#Sec1}
==========

Treatment for early stage breast cancer mostly consists of a combination of surgery, radiotherapy, chemotherapy and hormonal therapy. Chemotherapy can cause various side effects, such as nausea, vomiting, hair loss, fatigue, mucositis, cytopenia, ovarian failure and cardiac toxicity. In addition, numerous studies have described weight gain in women with breast cancer during chemotherapy \[[@CR1]--[@CR8]\].

Several reviews reported body weight gain during chemotherapy for breast cancer patients \[[@CR9]--[@CR15]\]. Weight gain during chemotherapy was first reported in 1978 by Dixon et al. \[[@CR16]\]. Mid-1990s reviews of the literature suggest that significant weight gain occurred in 50--96% of the breast cancer patients who received chemotherapy. Weight gain was reported to vary from 2.5 to 6.2 kg, while gains of more than 10 kg were not unusual \[[@CR13], [@CR14], [@CR17]\]. More recent studies report a lower prevalence of weight gain (35--85%), with weight gain varying between 1.4 to 5.0 kg \[[@CR6]--[@CR8], [@CR18]--[@CR20]\].

Body weight gain during chemotherapy treatment for breast cancer is undesirable, since it has negative influences on quality of life and health. Weight gain during treatment is associated with an negative affect on quality of life and self-esteem. In addition, several studies reported an increased risk of disease recurrence and poorer prognosis, however, these results are inconsistent \[[@CR10], [@CR15], [@CR21]--[@CR25]\]. A recent meta-analysis concluded that a weight gain of 10% or more after diagnosis of breast cancer is associated with higher all-cause mortality, mainly attributable to 1 study \[[@CR26]\].

There are important differences between studies that examined weight change during chemotherapy in breast cancer patients, which may partly explain the large variation in body weight changes observed between studies. First, the amount and type of chemotherapy changed over time, from cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in the 1970s and 1980s, to anthracyclines in the 1990s, to more taxane-based regimens nowadays \[[@CR27]--[@CR29]\]. Second, characteristics of included patients differed between studies. Some studies investigated only premenopausal women, while other studies included both, pre- and postmenopausal women. A third important difference is the time between the body weight measurements. Some studies followed patients only during chemotherapy with body weight measured before and shortly after chemotherapy. Other studies followed patients for a year or even longer with varying moments of weight measurements during follow-up. Fourth, the sample size varied substantially between studies, ranging from less than 10 till more than 200 participants. A fifth important difference is the study design: some studies retrieved body weight as reported in the medical records, while other studies had a prospective design with standardized measurements of body weight before, during and after chemotherapy.

Reviews regarding body weight gain during chemotherapy for breast cancer patients were narrative reviews and did not provide summary estimates for weight change so far. Therefore, the purpose of this meta-analysis was to quantify changes in body weight during chemotherapy for women with early stage breast cancer, and to assess which factors contributed to the heterogeneity between studies.

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

A comprehensive search of literature was conducted using PubMed, Scopus and Embase databases. Search term included: "body weight change", "body weight", "breast cancer", "breast neoplasm", "breast carcinoma", "breast tumor", "breast tumour", "breast adenoma", "mamma," "chemotherapy", "chemo" and "cytostatic" (see Additional file [1](#MOESM1){ref-type="media"} for more details). The search was limited to human studies, published in English up to and including December 2015. In addition, references listed in papers were screened for additional papers, resulting in the inclusion of one additional paper.

Paper selection {#Sec4}
---------------

Papers were included if they met the following criteria: early stage breast cancer patients treated with chemotherapy, type of chemotherapy reported, at least two measurements of body weight: one before and one after chemotherapy treatment. Both observational and intervention studies were included. Intervention studies were included if they included a control group receiving usual care; only the information of this usual care group was included in the meta-analysis.

One database was created and duplicate references were deleted. First, titles were screened on eligibility by two researchers (MB and RW). Secondly, abstracts were screened. If an abstract did not contain sufficient information to assess eligibility, the full-text was reviewed to assess eligibility. Communication letters, abstracts and poster of conferences were excluded.

Data extraction {#Sec5}
---------------

From each relevant paper, information on first author, year of publication, country, study design, sample size, characteristics of study population (baseline age, baseline height, baseline menopausal status), breast cancer stage, type of chemotherapy, duration of chemotherapy, follow-up period between measurements of weight, adjuvant/neo adjuvant chemotherapy, time points of weight assessment in relation to start and stop dates of chemotherapy, and weight or weight change (kg) with standard deviation (SD), 95% confidence interval or range were extracted and stored in a database.

Quality assessment {#Sec6}
------------------

To assess whether studies of lesser quality could have influenced the results, two researchers (MB and RW) independently assessed the quality of the included studies using an adapted version of the Newcastle-Ottawa Scale for assessing the quality of nonrandomised studies \[[@CR30]\]. Studies could get a maximum of 6 points, in four quality areas: 1) representativeness of the sample (information about number of people eligible and included); 2) loss to follow-up of participants (information about number lost to follow-up); 3) information about exposure (type of chemotherapy regimens); 4) assessment of the outcome (information how body weight was assessed). The rating system scores studies from 0 (low quality) to 6 points (high quality). A total score of 3 or less points was considered low quality, whereas a score of 4 or more points was considered high quality.

Statistical analysis {#Sec7}
--------------------

When no mean body weight change or SE was reported these were calculated if possible for each paper. When data on mean baseline weight and height were available we calculated the baseline mean BMI for the total group of participants using the formula: BMI = weight (kg) /height^2^ (m). If weight or weight change was reported for different types of chemotherapy or menopausal status separately, these results were included instead of the overall mean weight change. Random-effect models were used to calculate the mean and 95% confidence interval of the weight change during chemotherapy for breast cancer. Statistical heterogeneity between studies was assessed by the I^2^ statistic. I^2^ of 25%, 50% or 75% were interpreted as indicating low, moderate and high heterogeneity, respectively \[[@CR31]\]. To investigate potential sources of heterogeneity, we conducted stratified analyses. These included the factors: type of chemotherapy (CMF included vs no CMF included), sample size (*n* = \<100 vs *n*= \> 100), menopausal status (premenopausal, postmenopausal, both), baseline mean BMI (20.0--24.9 vs 25.0--29.9), study design (prospective vs chart review), second measurement of body weight (the end of chemotherapy /6 months after baseline' group and vs '6 months after chemotherapy/12 months after baseline' group), year of publication (before and including 2000 vs after 2000), country (US, Canada, Western Europe, Australia, Turkey, Korean) and study quality (low quality vs high quality). Of all factors included in the stratified analysis with data available of all estimates we conducted meta-regression analyses. We included the factors that were statistically significant in the univariate stratified analyses in a multivariate regression analysis. Regression coefficients, 95% confidence intervals and *p* values were reported. Sensitivity analyses were conducted by excluding one study at a time to explore whether one study markedly affected the results or highly contributed to the heterogeneity. A second sensitivity analysis was conducted by excluding the only intervention study included. Finally, sensitivity analyses were done excluding studies included \<50 participants, and excluding studies included \>200 participants to explore whether the smallest or largest studies markedly affect the results. Statistical analyses were conducted using STATA version 11 (StataCorp, College Station, TX). A *p*-value \<0.05 was considered statistically significant.

Results {#Sec8}
=======

The results of the literature search and study selection are summarized in Fig. [1](#Fig1){ref-type="fig"}. In total the database searches yielded 2445 references. After duplicates were deleted 2022 titles and 138 abstracts were screened for eligibility. A total of 52 full texts were screened, of which 27 papers were excluded, resulting in 25 eligible papers. Papers were excluded for the following reasons: full-text could not be obtained (*n* = 2); articles did not report a weight change (*n* = 4); articles included a variety of cancer types and did not report results for breast cancer separately (*n* = 3); articles did not report weight changes during chemotherapy (*n* = 3); weight change was not reported in kg, but only as percentage change (*n* = 4); type of chemotherapy was not reported (*n* = 4); chemotherapy was combined with other treatment e.g. radiotherapy (*n* = 4); only an intervention group (*n* = 2). One paper was excluded because a more recent paper about the same study was published. In total, 34 weight change estimates from 25 papers were included in this meta-analysis. Six papers reported results for weight gain in subgroups receiving different kind of chemotherapy treatments.Fig. 1Paper screening and data extraction progress

Characteristics of the participants and study designs {#Sec9}
-----------------------------------------------------

Characteristics of the studies included in this meta-analysis are shown in Table [1](#Tab1){ref-type="table"}. The 25 papers were published between 1985 and the end of 2015. Thirteen weight change estimates were published up to and including 2000 \[[@CR17], [@CR32]--[@CR38]\], and 21 after 2000 \[[@CR1], [@CR6]--[@CR8], [@CR12], [@CR18]--[@CR20], [@CR39]--[@CR47]\]. In total, 20 weight change estimates included patients treated with CMF. Sixteen weight estimates retrieved body weight from medical chart review. Eighteen had a prospective design of which one body weight estimate was an intervention study. Sample size of the body weight estimates varied from 8 to 483 participants. All papers used body weight before start of chemotherapy as baseline measure. For the second time point of measurement we created two groups: 1) 'the end of chemotherapy /6 months after baseline' group and 2) 'the 6 months after chemotherapy/12 months after baseline' group. The first group contained studies for which the second measurement was either directly after chemotherapy or 6 months after diagnosis, the second group all studies for which the second measurement was 6 months after chemotherapy or 12 months after diagnosis.Table 1Papers included in this meta-analysis of weight change during chemotherapy for women with early stage breast cancerFirst author, year of publicationYear of enrolmentStudy designSample (sample size, key characteristics)Type of chemotherapyFollow-upMean weight gain in kg (se) in total groupSubgroup analysis\
Mean weight gain in kg (se)Foltz, 1985 \[[@CR32]\]UNProspective*n* = 34, pre- and postmenopausal, stage II, adjuvantCMFpretreatment - 6 months2.99 (2.85)Heasman, 1985 \[[@CR33]\]1975--1981Retrospective Chart review*n* = 237, pre- and postmenopausal, adjuvant*n* = 46 single agent chemotherapy\
*n* = 112 CMF\
*n* = 79 CMF + prednisonePre -- posttreatment4.32 (0.23)Single agent: 2.72 (0.33)\
CMF: 3.65 (0.32)\
CMF + prednisone: 6.20 (0.4)Huntington, 1985 \[[@CR34]\]UNRetrospective Chart review*n* = 29, pre- and postmenopausal, adjuvant*n* = 18 CMF\
*n* = 11 CMFVPPre -- posttreatment4.58 (0.58)Premenopausal: 7.67 (0.89)\
Postmenopausal: 2.63 (0.72)\
Perimenopausal: 4.76 (0.12)Goodwin, 1988 \[[@CR35]\]1960--1984Retrospective Chart review*n* = 193, pre- and postmenopausal, adjuvant*n* = 113 CMF\
*n* = 80 CMF + prednisonPretreatment - 12 monthsCMF: 2.51 (0.24)\
CMF+ prednison 5.55 (0.62)Demark--Wahnefried, 1997 \[[@CR13]\]1993--1995Prospective*n* = 18, premenopausal, adjuvant*n* = 9 AC\
*n* = 5 CAF\
*n* = 1 CMF\
*n* = 1 CMF + leucovorin\
*n* = 1 A + CMF\
*n* = 1 AC + leucovorinPre- posttreatment0 (3.48)Aslani, 1999 \[[@CR36]\]UNProspective*n* = 25, pre- and postmenopausal, adjuvantCMFPre- posttreatment2.35 (0.62)Goodwin, 1999 \[[@CR37]\]1989--1996Prospective*n* = 176, pre- and postmenopausal, adjuvant*n* = 128 non-antracyclines\
*n* = 48 antracyclinesPretreatment - 12 months2.5 (0.36)Kutynec, 1999UNProspective*n* = 8, pre- and perimenopausal, adjuvantACPre- posttreatment0 (2.85)Demark-Wahnefried, 2001 \[[@CR12]\]1995--1999Prospective*n* = 36, premenopausal, adjuvant*n* = 17 doxorubicin regimens\
*n* = 12 doxorubicin regimens + tamoxifen,\
*n* = 6 CMF\
*n* = 1 CMF + tamoxifenPretreatment - 6 months2.2 (0.37)McInnes, 2001 \[[@CR1]\]UNRetrospective\
Chart review*n* = 44, pre- and postmenopausal, adjuvant*n* = 19 CMF - oral *n* = 6 CMF - iv *n* = 2 CAF - oral *n* = 9 CAF - iv *n* = 8 OtherPretreatment - 6 months3.4 (0.33)Del Rio, 2002 \[[@CR39]\]UNProspective*n* = 30, premenopausal, adjuvantCMFPretreatment - 6 months2.8 (0.56)Lankester, 2002 \[[@CR40]\]1998Retrospective\
Chart review*n* = 100, pre- and postmenopausal, adjuvant + neo-adjuvant*n* = 69 FEC\
*n* = 31 CMFPretreatment-before last cycle3.68 (0.4)Freedman, 2004 \[[@CR7]\]1999--2001Prospective*n* = 20, pre- and posttreatment, adjuvant*n* = 8 AC\
*n* = 10 AC + paclitaxel\
*n* = 2 AC + docetaxelPre- posttreatment−0.83 (0.81)Harvie, 2004 \[[@CR18]\]UNProspective*n* = 17, pre- and postmenopausal, adjuvant*n* = 12 FEC\
*n* = 5 CMFPre- posttreatment3.3 (1.02)Ingram, 2004 \[[@CR6]\]UNProspective*n* = 76, premenopausal, adjuvant*n* = 39 AC\
*n* = 33 CEF\
*n* = 4 CMFPre- posttreatment1.4 (0.39)AC: 1 (0.34)\
CEF: 1.5 (0.77)\
CMF: 5 (1.8)Kumar, 2004 \[[@CR41]\]UNProspective*n* = 170, pre- and postmenopausal, adjuvant*n* = 107 CA\
*n* = 45 CA + taxol\
*n* = 17 otherPre- posttreatment0.4 (1.13)Campbell, 2007 \[[@CR19]\]2001--2003Prospective*n* = 10, pre- and postmenopausal, adjuavnt*n* = 5 CEF\
*n* = 5 ACPre- posttreatment1.98 (5.06)Courneya, 2007 \[[@CR42]\]2003--2005Trial*n* = 82 pre- and postmenopausal, adjuvant*n* = 23 FE100C *n* = 20 AC *n* = 8 CE120F *n* = 3 other non-taxanen *n* = 10 TAC *n* = 14 AC-Taxanen *n* = 4 other taxanenPre- posttreatment1.2 (1.71)Makari-Judson, 2007 \[[@CR20]\]1997--2002Retrospective\
Chart review*n* = 123, pre- and postmenopausal, adjuvantAC, AC + taxanen, CAF, Doxorubicin + CMF, CMF or MF\
*n* = 109 antracycline containing CT\
*n* = 14 non antracyclinePretreatment - 12 months2.6 (0.57)Heideman, 2009 \[[@CR8]\]1974--2006Retrospective*n* = 31 (CT only), pre- and postmenopausal, adjuvantAC, EC, CMF, FAC, FEC, other incl herceptinPretreatment - 12 months2.2 (2.07)Heideman, 2009 \[[@CR8]\]1974--2006Retrospective*n* = 67 (Combined), pre- and postmenopausal, adjuvantAC, EC, CMF, FAC, FEC, other incl herceptinPretreatment - 12 months2.6 (1.69)Biglia, 20102007--2008Prospective*n* = 34, premenopausal, adjuvant*n* = 17 FEC\
*n* = 17 FEC + taxotereAfter surgery-end CT2.07 (0.45)Tredan, 2010 \[[@CR44]\]2004--2006Prospective*n* = 242, pre- and postmenopausal, adjuvant*n* = 110 anthracycline without taxane *n* = 156 anthracycline + taxane *n* = 2 taxane (1%)*n* = 4 missing dataPretreatment -- 6 months after CT0.7 (0.23)Premenopausal: 1.2 (0.31)\
Postmenopausal: 0.2 (0.33)Basaran, 2011 \[[@CR45]\]2003--2004Retrospective\
Chart review*n* = 171, pre- and postmenopausal, adjuvant*N* = 111 Antracycline based\
*N* = 55 Antracycline/taxane\
*N* = 5 No CTPre- posttreatment1.7 (0.94)Jeon, 2014 \[[@CR46]\]2005--2010Retrospective\
Chart review*N* = 108, pre- and postmenopausal, adjuvantTACPre- posttreatment3.64 (3.7)Winkels, 2014 \[[@CR47]\]2001--2010Retrospective\
Chart review*N* = 483, re and postmenopausal*n* = 289 antracycline based *n* = 170 antracycline + taxane *n* = 10 CMF *n* = 14 otherPre-posttreatment1.2 (0.25)*UN* unknown

Overall, data from 2620 women were included in this meta-analysis. The mean age of the study samples ranged from 39 to 56 years. Most papers included a combination of pre- and postmenopausal women. Seven papers included only premenopausal women. Two papers showed results separately for pre- and postmenopausal women. Table [2](#Tab2){ref-type="table"} gives an overview of the quality assessment of the studies included in this meta-analysis. Eight papers scored a total of three or less points for study quality and were assessed as low quality studies.Table 2Summary of the quality assessment of included studies using an adapted version of the Newcastle-Ottawa scale for assessing the quality of nonrandomised studiesFirst author, year of publicationRepresentativeness of sample (2 points)Loss to follow-up of participants (1 point)Information about exposure (1 point)Measurement of outcome (2 points)Total scoreFoltz, 1985 \[[@CR32]\]21115/6Heasman, 1985 \[[@CR33]\]21115/6Huntington, 1985 \[[@CR34]\]10113/6Goodwin, 1988 \[[@CR35]\]21115/6Demark-Wahnefried, 1997 \[[@CR13]\]11013/6Aslani, 1999 \[[@CR36]\]11114/6Goodwin, 1999 \[[@CR37]\]11024/6Kutynec, 1999 \[[@CR38]\]21115/6Demark-Wahnefried, 2001 \[[@CR12]\]21025/6McInnes, 2001 \[[@CR1]\]11013/6Del Rio, 2002 \[[@CR39]\]11103/6Lankester, 2002 \[[@CR40]\]11013/6Freedman, 2004 \[[@CR7]\]11024/6Harvie, 2004 \[[@CR18]\]11024/6Ingram, 2004 \[[@CR6]\]21126/6Kumar, 2004 \[[@CR41]\]21014/6Campbell, 2007 \[[@CR19]\]11024/6Courneya, 2007 \[[@CR27]\]21014/6Makari-Judson, 2007 \[[@CR20]\]21014/6Heideman, 2009 \[[@CR8]\]21014/6Biglia, 201011002/6Tredan, 2010 \[[@CR44]\]11013/6Basaran, 2011 \[[@CR45]\]10012/6Jeon, 2014 \[[@CR46]\]11114/6Winkels, 2014 \[[@CR47]\]21115/6(1) Representativeness of sample (2 points: extensive information on number of people eligible and included, 1 point: extensive information about recruitment, but not about number of people eligible and included, 0 points: only brief information about recruitment. (2) Loss to follow-up of participants (1 point: information about number lost to follow-up; 0 points: no information about number lost to follow-up). (3) information about exposure (1 point: results are given separate for different chemotherapy regimens, 0 points: results are not separated out for chemotherapy regimens). (4) assessment of the outcome (2 points: measurement protocol for body weight, 1 point: body weight information for chart review or measurement without protocol, 0 points: no information on how body weight was assessed). The rating system scores studies from 0 (low quality) to 6 points (high quality)

Overall estimate {#Sec10}
----------------

Mean weight change reported in the papers ranged from −0.8 to 7.7 kg. A gain in body weight was reported in 31 of the 34 estimates, Fig. [2](#Fig2){ref-type="fig"}. The pooled mean weight change was 2.7 kg (95% CI: 2.0--3.3) with a heterogeneity of 94.2%. To further explore this high heterogeneity, stratified analyses were conducted.Fig. 2Weight change during chemotherapy for early stage breast cancer. Mean weight changes in individual estimates are depicted as squares with 95% confidence intervals (CI). Pooled estimates with 95% CI are depicted as open diamonds

Stratified and sensitivity analyses {#Sec11}
-----------------------------------

Body weight change estimates were stratified by type of chemotherapy, sample size, menopausal status, baseline BMI, study design, time between body weight measurements, year of publication, country, and study quality see Table [3](#Tab3){ref-type="table"}. Overall, weight gain was observed in all strata. Stratified analyses did not substantially reduce heterogeneity. The high heterogeneity remained for most subgroups except for the body weight change estimates in studies with a normal mean BMI at baseline (I^2^ = 45.1%) who had a low heterogeneity and estimates not including CMF (I^2^ = 74.7%), including studies with a mean BMI \>25 at baseline (I^2^ = 73.2%) and for prospective studies (I^2^ = 69.5%), which all showed a moderate heterogeneity.Table 3stratified pooled mean weight change and 95% confidence interval in women during chemotherapy treatment for early stage breast cancerNo of estimatesPooled weight change kg95% CI^a^I^2b^Overall  All342.72.0, 7.594.2Type Chemotherapy  CMF included203.52.7, 4.393.7  No CMF141.40.7, 2.074.7Menopausal status  Premenopausal92.61.5, 3.686.9  Postmenopausal21.3−1.1, 3.789.4  Perimenopausal14.84.5, 5.0  Combination222.72.0, 3.488.3Baseline mean BMI  20.0--24.960.5−0.4; 1.345.1  25.0--29.9152.41.8; 3.673.2  Unknown133.52.6; 4.595.4Follow-up93.8  end of chemotherapy / 6 months after baseline262.72.0; 3.590.9  6 months after chemotherapy / 12 months after baseline82.41.3; 3.4Type of study  Chart review163.62.8, 4.494.8  Prospective181.61.1, 2.269.5Publication year  Before and including 2000133.82.9, 4.793.3  After 2000211.91.3, 2.581.6Sample Size   ≤ 100233.02.2, 3.992.7   \> 100112.11.3, 2.890.1Country  United States102.81.6; 4.193.4  Canada123.12.1; 4.191.8  Western Europe92.01.1; 2.886.2  Australia12.41.1;3.6  Turkey11.7−0.1; 3.5  Korea13.6−3.6; 10.9Study quality  Low quality112.91.6; 4.196.7  High quality232.51.8; 3.288.8^a^Confidence interval^b^1^2^ = the percentage heterogeneity due to between-study variation

Sensitivity analyses excluding one study at a time did not markedly influence the overall result of weight change (range 2.4--2.8 kg) nor did importantly affect the amount of heterogeneity (range I^2^ 89.2--94.6%), neither did excluding the smallest or largest studies. In addition, excluding the intervention study did also not markedly influence the overall result of weight change 2.7 kg (95% CI: 2.0--3.4) \[[@CR42]\].

Of the 21 body weight change estimates from studies published after 2000, 10 estimates included women treated with CMF. The main weight change in the body weight change estimates from studies after 2000 including women treated with CMF was 2.8 kg (95% CI: 2.0, 3.5) compared to 1.0 kg (95% CI: 0.5, 1.5) in those that did not include women treated with CMF.

Meta-regression analysis {#Sec12}
------------------------

Results of the meta-regression analyses are shown in Table [4](#Tab4){ref-type="table"}. Results of the univariate model showed that weight gain was significantly different for body weight estimates from studies including CMF vs estimates from studies not including CMF, for studies using chart review vs prospective studies, and for studies published before 2000 vs studies published after 2000. In the multivariate model, we studied the combined effect of type of chemotherapy, study design and year of publication. In this model type of chemotherapy and year of publication remained significantly associated with body weight change, although the body weight change estimates were attenuated. Study design was no longer statistically significantly associated with body weight change in the multivariate model. The residual I^2^ for the multivariable regression model was 84.8%, indicating that these factors explained only a small part of the heterogeneity.Table 4Results from multivariate meta-regression analysis on weight change in subgroups of early stage breast cancer patients during chemotherapyUnadjustedAdjusted^d^RC^a^SE^b^95% CI^c^*P*-valueRCSE95% CI*P*-valueType chemotherapy  No CMFrefref  CMF included2.20.61.1, 3.3\<0.011.40.60.3, 2.60.02Menopausal status  Premenopausalref  Postmenopausal−1.31.4−4.1, 1.50.36  Perimenopausal2.21.8−1.5, 5.80.23  Combination0.10.8−1.5, 1.60.91Follow-up  end of chemotherapy / 6 months after baselineref  6 months after chemotherapy / 12 months after baseline−0.10.1−0.3; 0.20.64Type of studie  Chart reviewrefref  Prospective−2.00.6−3.1, −0.8\<0.01−0.70.6−1.9, 0.50.24Publication year   After 2000refref   Before and including 20001.90.60.8, 3.1\<0.011.30.50.2, 2.30.02Sample Size   ≤ 100ref   \> 100−1.00.7−2.3, 0.40.15Country  United Statesref  Canada−0.20.9−1.5; 2.00.79  Western Europe−0.80.9−2.6; 1.00.39  Australia−0.51.9−4.5; 3.50.80  Turkey−1.12.1−5.4; 3.10.58  Korea0.84.1−7.7; 9.30.85Quality assessment  Low Qualityref  High Quality−0.40.7−1.8; 1.00.58^a^Regression coefficient^b^Standard error^c^Confidence interval^d^Adjusted for, type of chemotherapy, type of study and publication year

Discussion {#Sec13}
==========

The present work is the first meta-analysis that quantified changes in body weight during chemotherapy in women with early stage breast cancer. Based on 25 papers, a mean weight gain of 2.7 kg (95% CI: 2.0--3.3) was observed with a heterogeneity of 94.2%. Stratified analysis showed weight gain in all strata, but the strata could only marginally explain the heterogeneity. Adjusted weight gain estimates based on body weight estimates from studies including patients treated with CMF and papers published before 2000 were larger compared to estimates from studies in which CMF was not included and papers published after 2000. Despite the high heterogeneity which could only partly be explained, the results of this meta-analysis suggest constant and significant weight gain during chemotherapy for women with early stage breast cancer.

Treatment for breast cancer has changed over time. Before the 1990s, only CMF was used as chemotherapy regime, while during the 90s the use of anthracyclines gradually increased. In studies after 2004, taxane-based chemotherapy was introduced as a treatment for early stage breast cancer. In the current meta-analysis, CMF emerged as a chemotherapy associated with weight gain, which use has importantly decreased over time. However, our meta-analyses also showed that in studies published after the year 2000 the mean weight gain was still considerable 1.3 kg. Stratified by type of chemotherapy, the mean weight change from studies published after 2000 and including women treated with CMF was 2.8 kg compared to 1.0 kg in those that did not include women treated with CMF. These data suggest that the abandoning of CMF as the chemotherapeutic regimen of choice could be an important reason for observing less weight gain in more recent studies. Independently of CMF, time of publication was associated with weight gain. A possible reason why studies after 2000 observed less weight gain relative to earlier studies could be the incremental use of taxanes in more recent years. However, as the studies included in this meta-analysis did not all provide detailed information on type of chemotherapy, we can only speculate on that.

Another possible explanation for differences in weight gain between older and more recent studies could be age and BMI at baseline. However, we did not see a difference in baseline age and mean BMI comparing older and more recent studies. Yet, since most studies included in this meta-analysis did not provide detailed information and stratified results on baseline BMI, we could not explore this in detail.

Weight gain appeared to be less in prospective studies than in chart review studies in our meta-analysis. A possible explanation for this finding is, that in prospective studies, data usually were collected as part of a cohort or other observational study. These studies could potentially include a selected (e.g. high SES) population, which make them less generalizable to the general population. Chart review papers usually included all patients treated with chemotherapy in a retrospective period of time, but completeness of data was not clearly reported in all studies. Thus both, chart reviews and prospective studies may suffer from incomplete data and selection issues, but as studies did not provide detailed information on response rates and possible selection, we could not explore this further in our meta-analysis. Moreover, stratified results on study quality did not show any differences between studies considered as low quality compared to studies considered of high quality, neither did stratifying on study quality reduce heterogeneity.

An earlier narrative review suggested that women with a normal BMI at baseline were more likely to gain weight compared to women who were overweight at diagnosis \[[@CR15]\], however other studies did not confirm this \[[@CR37], [@CR44]\] Since only one study included in this meta-analysis reported results for weight change stratified in categories of baseline BMI, we could not study this in great detail. Nevertheless, our analyses suggested a lower weight gain in studies with a mean normal BMI at baseline compared to studies with mean BMI \> 25 at baseline. These results should be interpreted carefully, since they represents mean BMI for the total study, which does not mean that all women in that study fall within that BMI category. If the man BMI of a study population is lower, other possible confounding factors may also differ from studies in which mean BMI is higher. However, as this is speculative, and data on other confounding factors is limited, we could not study this further. An important factor in the interpretation of our results is that heterogeneity of our estimates remained high despite elaborate analyses to explore possible sources of heterogeneity, including stratification and meta-regression. This high heterogeneity suggests that other, less studied factors may importantly contribute to weight gain during chemotherapy. A factor that could contribute is ovarian failure which is especially relevant for premenopausal women. This ovarian failure impacts hormonal levels, which may possibly be related to subsequent weight gain. Nevertheless, in the current meta-analyses we did not observe differences in weight gain between pre- and postmenopausal women, possibly because only a small part of the studies stratified for menopausal status \[[@CR48]\]. Weight gain may also be explained by common side-effects of chemotherapy such as fatigue, potentially reducing habitual physical activity \[[@CR17], [@CR49]\]. Recently, special programs are implemented in breast cancer care in various countries stimulating physical activity. These added interventions may explain differences between older and more recent studies. Also, chemotherapy may induce changes in taste and smell possibly leading to changes in dietary eating patterns which could influence body weight \[[@CR50]\]. However, little research has focused on these sensory effects. Furthermore, reductions in energy expenditure in rest have been reported during and after chemotherapy which may lead to an increase in body weight \[[@CR15], [@CR10]\]. As most studies did not publish on these potential factors, we could not explore whether they were possible sources of heterogeneity in our meta-analysis.

A limitation of our study is that we could not explore duration of chemotherapy as a source of heterogeneity. Chemotherapy duration has decreased nowadays. Literature suggest that duration of chemotherapy could be an important factor to weight gain \[[@CR15], [@CR17], [@CR10]\]. In this meta-analyse it was not possible to explore this since most studies did not report the duration of chemotherapy.

Another limitation is that we used the year that the manuscript was published and not the years the participants were enrolled into the study: time between conducting the study and publishing the results may vary between studies. Although year of enrolment would have been preferable, for 13 estimates this information was available. A sensitivity analysis using only the 21 estimates that had this information available showed a comparable trend of a decrease in weight gain for more recent studies (data not shown).

Also we could only study changes in weight, but not in fat or fat-free mass. Future studies should provide more detailed information on body weight trajectories and preferably body composition, as changes in fat and lean mass may be more clinically relevant. In addition, future studies should also report percentage of women with a significant weight loss, gain or maintenance rather than only mean weight change, so it is possible to establish the clinical magnitude of changes in body weight during chemotherapy.

A strength of this study is that it is, to the best of our knowledge, the first meta-analysis conducted on weight gain in breast cancer women during chemotherapy. A comprehensive literature search was conducted including an additional hand search. This makes the potential of missing any published data in English unlikely.

Conclusions {#Sec14}
===========

In conclusion, our results indicate that women generally gain weight during chemotherapy for early stage breast cancer. This weight gain is more pronounced in women treated with CMF and is greater in studies published before 2000. Although weight gain after chemotherapy has decreased over the course of time, weight gain is still substantial and deserves clinical attention.
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